Add a Thiazide-Like Diuretic (Chlorthalidone or Indapamide) as Your Next Step
You should add a thiazide-like diuretic—specifically chlorthalidone or indapamide—to the current regimen of losartan 100mg and amlodipine 10mg. This creates the guideline-recommended first-line triple therapy for resistant hypertension 1, 2.
Why This Specific Recommendation
The 2025 AHA/ACC guidelines explicitly define your patient's situation as resistant hypertension: blood pressure remains above goal despite treatment with 3 antihypertensive medications with complementary mechanisms of action, including a diuretic at maximally tolerated doses 1, 2. However, your patient is currently only on 2 medications (an ARB and a CCB), so you haven't yet achieved the optimal first-line triple therapy.
The guidelines are crystal clear that antihypertensive therapy should start with—or build toward—a combination of:
- An ACE inhibitor or ARB (you have losartan ✓)
- A CCB (you have amlodipine 10mg ✓)
- A thiazide-like diuretic (you're missing this)
Critical Distinction: Thiazide-LIKE vs Thiazide-TYPE
Use chlorthalidone or indapamide, NOT hydrochlorothiazide (HCTZ). The guidelines specifically note that replacing thiazide-type diuretics (HCTZ, bendroflumethiazide) with thiazide-like diuretics (chlorthalidone, indapamide) offers additional BP reduction and cardiovascular protection 1. This is a crucial detail that impacts both morbidity and mortality outcomes.
Before Adding the Diuretic: Essential Evaluation
The guidelines mandate a more detailed evaluation for secondary causes of hypertension at this stage 1, 2. Specifically assess for:
- Medication interference: NSAIDs, decongestants, oral contraceptives, corticosteroids, stimulants—these can elevate BP and should be discontinued if possible 1
- Primary aldosteronism: Most common secondary cause in resistant hypertension
- Obstructive sleep apnea: Highly prevalent in resistant hypertension
- Renal parenchymal disease or renovascular disease
- Volume status: Confirm the patient isn't volume/salt depleted, which could cause symptomatic hypotension when adding therapy 3
If Triple Therapy Still Fails: Add a Mineralocorticoid Receptor Antagonist
If BP remains uncontrolled after optimizing the ARB + CCB + thiazide-like diuretic combination, add spironolactone or eplerenone (mineralocorticoid receptor antagonist, MRA) 1, 2. This is a Class 1, Level B-R recommendation specifically for patients with:
- eGFR ≥45 mL/min/1.73 m²
- Uncontrolled resistant hypertension despite optimal first-line triple therapy
The MRA addition is the single most evidence-based fourth agent for resistant hypertension.
Monitoring Requirements
When adding a diuretic (and especially later if adding an MRA):
- Monitor serum potassium periodically 3. Losartan can increase potassium, and while the diuretic may offset this, you need to verify
- Monitor renal function 3. Patients on ARBs are at risk for renal function deterioration, particularly with volume depletion
- Avoid potassium supplements and salt substitutes containing potassium while on losartan 3
Common Pitfall to Avoid
Do not simply increase amlodipine beyond 10mg—this is already the maximum FDA-approved dose 4. While one study suggested that increasing amlodipine to 10mg was more effective than adding indapamide 5, you've already maximized this option. The guideline-directed approach is to complete the triple therapy with a thiazide-like diuretic.
Alternative Fourth-Line Agents (If MRA Contraindicated)
If the patient cannot tolerate or has contraindications to MRA after completing triple therapy, reasonable alternatives include 2:
- Amiloride
- Beta-blockers
- Alpha-blockers
- Central sympatholytic drugs
However, these are clearly second-choice options compared to MRA for the fourth agent.